The past two years have been tough for Magenta, which received a clinical hold on its lead candidate MGTA-117 in July 2021 and undertook a company restructuring in April 2022.
The biotech’s latest setback came last week, when it announced an adult study volunteer had died during a Phase 1/2 trial for MGTA-117, an antibody drug used to condition patients for stem cell transplants.
In December, Magenta had announced it stopped dosing some patients in the trial after two of three participants given the highest tested dose experienced serious side effects, including elevated liver enzyme counts and respiratory issues. The patient who died had received the second-highest dose tested.
